Buzzworthy Updates, Insect Allergy Practice Parameter Webinar

October 28, 2026

The 2026 Stinging Insect Allergy Practice Parameter represents the first comprehensive update since 2016, incorporating a decade of new evidence on epidemiology, diagnostic testing, risk stratification, and venom immunotherapy. Despite these advances, clinicians across practice settings continue to face challenging, nuanced questions in the day-to-day management of patients with stinging insect hypersensitivity, questions that existing resources have not fully addressed.

This webinar features three experts from the 2026 Practice Parameter writing group, each addressing a focused content area through the lens of questions that routinely arise in clinical practice. The format is intentionally practical: rather than comprehensively reviewing the parameter, faculty will highlight the updates most relevant to front-line clinicians and directly address the management dilemmas that allergists encounter most frequently.

This webinar is designed to complement the ACAAI 2026 Annual Meeting venom symposium (Venom Immunotherapy: Bridging Evidence and Practice in the 2026 Parameter Update, Session 5082, November 15, 2026), which focuses on diagnostic pathways, VIT indications, and complex case management. Both attendees will receive comprehensive, non-overlapping coverage of the full Practice Parameter update.

Accreditation
Accreditation with Commendation - ACCME The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

Allergists, advanced practice providers, and office staff.

Learning Objectives

Upon completion of this activity, learners should be able to:

  1. Apply updated epidemiologic data on stinging insect fatalities, exposure patterns, and geographic and occupational risk to patient counseling and clinical decision-making.
  2. Recognize the unique diagnostic and management considerations for fire ant and stinging ant hypersensitivity, including indications for immunotherapy.
  3. Evaluate patients with elevated baseline serum tryptase or suspected hereditary alpha tryptasemia (HαT) using an evidence-based framework for risk stratification and individualized management.
  4. Identify patients who warrant further evaluation for underlying mast cell disease in the context of stinging insect anaphylaxis.
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

Advertising, marketing, or communication firms whose clients are ineligible companies
Bio-medical startups that have begun a governmental regulatory approval process
Compounding pharmacies that manufacture proprietary compounds
Device manufacturers or distributors
Diagnostic labs that sell proprietary products
Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
Manufacturers of health-related wearable products
Pharmaceutical companies or distributors
Pharmacy benefit managers
Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

Course summary

Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
10/28/2026
Course expires: 
10/28/2027
Event starts: 
10/28/2026 - 7:00pm CDT
Event ends: 
10/28/2026 - 8:00pm CDT
Add to calendar: 
Rating: 
0

Moderator: 
Karla Adams, MD
A Professor of Pediatrics and a practicing Allergist in San Antonio, Texas. She obtained her medical degree from the Uniformed Services University then completed a Pediatrics residency and Allergy and Immunology Fellowship at the San Antonio Uniformed Services Health Education Consortium in San Antonio, TX. She is currently the Program Director for the Allergy and Immunology Fellowship at Wilford Hall Ambulatory Surgical Center, San Antonio, TX.
Disclosure: Nothing to disclose

Speakers: 
John Carlson, MD, PhD
An allergist/immunologist and medical entomologist working in the Ochsner Health System, located in New Orleans, Louisiana. His research and clinical work have focused on the immune reactions to arthropods, including venom-induced anaphylaxis and asthmatic reactions to cockroach allergens. 
Disclosure: Nothing to disclose

Jeremy McMurray, MD
A board-certified allergist-immunologist at Walter Reed National Military Medical Center and assistant professor of pediatrics at the Uniformed Services University. He co-leads the Walter Reed AIM Center of Excellence in systemic mastocytosis clinical care and research and serves on the workgroup writing the updated stinging insect allergy practice parameters. His work focuses on venom anaphylaxis and systemic mastocytosis, with multiple peer-reviewed publications in both areas.
Disclosure: Advisor: Cogent Biosciences

James (Jim) Quinn, MD 
Associate Program Director of the Allergy/Immunology Fellowship at Wilford Hall in San Antonio.  He is a Professor of Medicine at the Uniformed Service University of the Health Sciences.
Disclosure: Nothing to disclose

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Please login or create an account to take this course.